NicholsDE, NicholsCD, HendricksPS. Proposed consensus statement on defining psychedelic drugs. Psychedelic Med (New Rochelle), 2023; 1(1):12–13.
2.
RockhillKM, BlackJC, LadkaMS, et al.The rise of psilocybin use in the United States: A multisource observational study. Ann Intern Med, 2025; 178(7):1052–1054.
3.
WalshCA, GorfinkelL, ShmulewitzD, et al.Use of lysergic acid diethylamide by major depression status. JAMA Psychiatry, 2024; 81(1):89–96.
4.
YockeyRA, VidourekRA, KingKA. Trends in LSD use among US adults: 2015–2018. Drug Alcohol Depend, 2020; 212:108071.
5.
BarnettBS, AnandA, DeweyEN, et al.Perceived risk of trying lysergic acid diethylamide in the United States from 2015 to 2019: Are Americans assessing lysergic acid Diethylamide’s risk profile more favorably? Psychedelic Med (New Rochelle), 2024; 2(2):74–86.
6.
HsuT-W, TsaiC-K, KaoY-C, et al.Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: Systematic review and Bayesian network meta-analysis. BMJ, 2024; 386:e078607.
7.
SiegelJS, DailyJE, PerryDA, et al.Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry, 2023; 80(1):77–83.
8.
YaoY, GuoD, LuT-S, et al.Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Res, 2024; 335:115886.
9.
CarvalhoLC, EncantadoJ, KettnerH, et al.A scoping review of research in naturalistic studies with psychedelics. J Psychoactive Drugs, 2025:1–14.
10.
NayakSM, JacksonH, SepedaND, et al.Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: Results from a prospective, longitudinal survey. Front Psychiatry, 2023; 14:1199642.
11.
SimonssonO, HendricksPS, SwordsCM, et al.Naturalistic psychedelic use and changes in depressive symptoms. J Affect Disord, 2025; 390:119857.
12.
MyranDT, MacDonald-SpracklinR, PuglieseM, et al.Hospital-based care for hallucinogens and risk of mania and bipolar disorder: A population-based cohort study. PLoS Med, 2025; 22(12):e1004805.
13.
MyranDT, PuglieseM, XiaoJ, et al.Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder. JAMA Psychiatry, 2025; 82(2):142–150.
14.
BarnettBS. Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health. J Psychopharmacol, 2022; 36(10):1097–1099.
15.
Carhart-HarrisRL, RosemanL, HaijenE, et al.Psychedelics and the essential importance of context. J Psychopharmacol, 2018; 32(7):725–731.
16.
YadenDB, GoldySP, WeissB, et al.Clinically relevant acute subjective effects of psychedelics beyond mystical experience. Nat Rev Psychol, 2024; 3(9):606–621.
17.
CraigP, KatikireddiSV, LeylandA, et al.Natural experiments: An overview of methods, approaches, and contributions to public health intervention research. Annu Rev Public Health, 2017; 38(1):39–56.
